# EDGAR Filing Document

**Accession Number:** 0001347178
**File Stem:** 0000000000-23-001606
**Filing Date:** 2023-2
**Character Count:** 3460
**Document Hash:** de8179b6ebac396d1d5f16a4b1f9a375
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-001606.hdr.sgml**: 20230605

**ACCESSION NUMBER**: 0000000000-23-001606

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230216

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vanda Pharmaceuticals Inc.
- **CENTRAL INDEX KEY:** 0001347178
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 030491827
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 2200 PENNSYLVANIA AVE NW
- **STREET 2:** SUITE 300E
- **CITY:** WASHINGTON
- **STATE:** DC
- **ZIP:** 20037
- **BUSINESS PHONE:** 202-734-3400

**MAIL ADDRESS:**
- **STREET 1:** 2200 PENNSYLVANIA AVE NW
- **STREET 2:** SUITE 300E
- **CITY:** WASHINGTON
- **STATE:** DC
- **ZIP:** 20037
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-23-029269

## Text-Extract

```

United States securities and exchange commission logo

                          February 16, 2023

       Dr. Mihael Polymeropoulos
       President and Chief Executive Officer
       Vanda Pharmaceuticals Inc.
       2200 Pennsylvania Avenue NW, Suite 300E
       Washington, DC 20037

                                                        Re: Vanda
Pharmaceuticals Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed February 9,
2023
                                                            File No. 333-269654

       Dear Dr. Mihael Polymeropoulos:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Cindy
Polynice at 202-551-8707 with any questions.

                          Sincerely,

                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Gregg A. Griner, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

February 16, 2023

Dr. Mihael Polymeropoulos
President and Chief Executive Officer
Vanda Pharmaceuticals Inc.
2200 Pennsylvania Avenue NW, Suite 300E
Washington, DC 20037

**Re: Vanda Pharmaceuticals Inc.**
**Registration Statement on Form S-3**
**Filed February 9, 2023**
**File No. 333-269654**

Dear Dr. Mihael Polymeropoulos:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Cindy Polynice at 202-551-8707 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Gregg A. Griner, Esq.